HK1256480A1 - 用於改进nrf2激活的组合物和其使用方法 - Google Patents

用於改进nrf2激活的组合物和其使用方法 Download PDF

Info

Publication number
HK1256480A1
HK1256480A1 HK18115518.1A HK18115518A HK1256480A1 HK 1256480 A1 HK1256480 A1 HK 1256480A1 HK 18115518 A HK18115518 A HK 18115518A HK 1256480 A1 HK1256480 A1 HK 1256480A1
Authority
HK
Hong Kong
Prior art keywords
extract
luteolin
composition
rosemary
ginger
Prior art date
Application number
HK18115518.1A
Other languages
English (en)
Chinese (zh)
Inventor
布鲁克斯‧迈克尔‧海伯特松
布魯克斯‧邁克爾‧海伯特松
乔‧米尔顿‧麦考德
喬‧米爾頓‧麥考德
Original Assignee
路径生物科学有限公司
路徑生物科學有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 路径生物科学有限公司, 路徑生物科學有限公司 filed Critical 路径生物科学有限公司
Publication of HK1256480A1 publication Critical patent/HK1256480A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
HK18115518.1A 2015-09-03 2016-09-02 用於改进nrf2激活的组合物和其使用方法 HK1256480A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562214175P 2015-09-03 2015-09-03
US62/214,175 2015-09-03
US201662355810P 2016-06-28 2016-06-28
US62/355,810 2016-06-28
PCT/US2016/050292 WO2017041054A1 (en) 2015-09-03 2016-09-02 Compositions for improved nrf2 activation and methods of their use

Publications (1)

Publication Number Publication Date
HK1256480A1 true HK1256480A1 (zh) 2019-09-27

Family

ID=58188643

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18115518.1A HK1256480A1 (zh) 2015-09-03 2016-09-02 用於改进nrf2激活的组合物和其使用方法

Country Status (9)

Country Link
US (1) US11413269B2 (enExample)
JP (1) JP6901787B2 (enExample)
CN (2) CN108136209A (enExample)
CL (1) CL2018000573A1 (enExample)
CO (1) CO2018003454A2 (enExample)
HK (1) HK1256480A1 (enExample)
MX (2) MX394479B (enExample)
PE (1) PE20190380A1 (enExample)
WO (1) WO2017041054A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220354916A1 (en) * 2015-09-03 2022-11-10 Pathways Bioscience, Llc Compositions for improved nrf2 activation and methods of their use
US10993981B2 (en) * 2016-07-11 2021-05-04 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organiation (Aro), (Volcani Center) Compositions for treatment of follicular tonsillitis using an emulsion based on rosemary extract and oregano essential oil
WO2018197394A1 (en) * 2017-04-27 2018-11-01 Dsm Ip Assets B.V. Use of withania somnifera extract to protect against air pollution related diseases
WO2026163006A1 (en) * 2025-01-28 2026-08-06 Access Business Group International Llc Compositions, methods comprising rosmarinus officinalis and zingiber officinale extracts for improving and/or extending healthspan

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888514A (en) * 1997-05-23 1999-03-30 Weisman; Bernard Natural composition for treating bone or joint inflammation
US9265808B2 (en) * 2004-03-23 2016-02-23 Lifeline Nutraceuticals Corporation Compositions for alleviating inflammation and oxidative stress in a mammal
WO2006073042A1 (ja) * 2005-01-05 2006-07-13 Toagosei Co., Ltd. Ｎｒｆ２依存遺伝子の活性化剤
RU2008143294A (ru) * 2006-04-03 2010-05-10 Нестек С.А. (Ch) Питательные композиции для стимуляции роста костей и поддержания здорового состояния костей и относящиеся к ним способы
US8142806B2 (en) 2008-03-10 2012-03-27 University Of Louisville Research Foundation, Inc. Methods and compositions for controlled delivery of phytochemical agents
JP5608646B2 (ja) 2008-07-31 2014-10-15 シャクリー コーポレーション 向上した抗酸化活性を有するマスカダイン組成物
JP2011057654A (ja) 2009-09-14 2011-03-24 Iwate Univ メタボリックシンドローム治療又は予防薬、及び脂肪細胞分化抑制方法
WO2011075843A1 (en) 2009-12-24 2011-06-30 The Royal Institution For The Avancement Of Learning/Mcgill University Compositions and methods for preventing and treating diseases and environmentally induced health disorders
KR101254847B1 (ko) * 2010-05-27 2013-04-15 한림대학교 산학협력단 실리비닌(silibinin)을 포함하는 골다공증 치료 및 예방용 조성물
WO2012142511A2 (en) 2011-04-15 2012-10-18 Md Matrix Health Llc Dba Md Matrix Health Inc Orthomolecular compositions and their use in stabilizing the extracellular matrix
WO2013108056A1 (es) * 2012-01-16 2013-07-25 Velez-Rivera Hector De Jesus Fitocomposición para el tratamiento de dolores relacionados con enfermedades articulares
JP2013209351A (ja) * 2012-03-30 2013-10-10 Sunstar Inc 抗酸化機能亢進剤
US20140287071A1 (en) * 2013-01-17 2014-09-25 Lifevantage Corporation Veterinary supplements
WO2014151891A1 (en) * 2013-03-14 2014-09-25 Walley Darlene Topical products
CA2917921C (en) * 2013-07-17 2021-08-03 Council Of Scientific & Industrial Research Pharmaceutical composition for the treatment of diminution of bone tissue
WO2016037971A1 (en) * 2014-09-08 2016-03-17 Bios Line S.P.A. Compositions comprising glucosinolates precursors of sulforaphane in combination with extracts of rosemary

Also Published As

Publication number Publication date
CO2018003454A2 (es) 2018-08-31
CL2018000573A1 (es) 2019-01-11
MX2022009446A (es) 2022-09-05
MX2018002743A (es) 2018-06-06
CN120754114A (zh) 2025-10-10
JP6901787B2 (ja) 2021-07-14
PE20190380A1 (es) 2019-03-08
JP2018529763A (ja) 2018-10-11
WO2017041054A1 (en) 2017-03-09
US11413269B2 (en) 2022-08-16
US20180250264A1 (en) 2018-09-06
CN108136209A (zh) 2018-06-08
MX394479B (es) 2025-03-24

Similar Documents

Publication Publication Date Title
Wu et al. Anti-inflammatory/Anti-oxidative stress activities and differential regulation of Nrf2-mediated genes by non-polar fractions of tea Chrysanthemum zawadskii and licorice Glycyrrhiza uralensis
Treasure et al. Exploring the anti‐inflammatory activity of sulforaphane
Wu et al. Anti-inflammatory effects of 4′-demethylnobiletin, a major metabolite of nobiletin
Lu et al. Saikosaponin a and its epimer saikosaponin d exhibit anti-inflammatory activity by suppressing activation of NF-κB signaling pathway
TWI757228B (zh) 含有槲皮素配糖體之筋萎縮抑制劑
Boojar et al. Overview of Silibinin anti-tumor effects
Shin et al. Anti-inflammatory effects of glycyrol isolated from Glycyrrhiza uralensis in LPS-stimulated RAW264. 7 macrophages
Choi et al. Desoxyrhapontigenin up-regulates Nrf2-mediated heme oxygenase-1 expression in macrophages and inflammatory lung injury
Yang et al. Anti-inflammatory effect of prunetin via the suppression of NF-κB pathway
Xiao et al. Indigo naturalis suppresses colonic oxidative stress and Th1/Th17 responses of DSS‐induced colitis in mice
Balstad et al. Coffee, broccoli and spices are strong inducers of electrophile response element‐dependent transcription in vitro and in vivo–Studies in electrophile response element transgenic mice
US20120071550A1 (en) Synergistic combinations of cartonoids and polyphenols
Xu et al. Effects of hydroxysafflor yellow A on the activity and mRNA expression of four CYP isozymes in rats
Vitali et al. Dipotassium glycyrrhizate via HMGB1 or AMPK signaling suppresses oxidative stress during intestinal inflammation
Zhang et al. Effects of myricitrin and relevant molecular mechanisms
Soliman et al. Protective Impacts of Moringa oleifera Leaf Extract against Methotrexate‐Induced Oxidative Stress and Apoptosis on Mouse Spleen
Aditya et al. Antiangiogenic effect of combined treatment with curcumin and genistein on human prostate cancer cell line
US20180271803A1 (en) Compositions and methods for treatment or prevention of oral mucositis
CN120754114A (zh) 用于改进nrf2激活的组合物和其使用方法
Al‐kuraishy et al. The possible role of nuclear factor erythroid‐2‐related factor 2 activators in the management of Covid‐19
Wu et al. Total C-21 steroidal glycosides, isolated from the root tuber of Cynanchum auriculatum Royle ex Wight, attenuate hydrogen peroxide-induced oxidative injury and inflammation in L02 cells
Sani et al. Inhibitory effects of curcuminoids on dexamethasone-induced muscle atrophy in differentiation of C2C12 cells
Yadavalli et al. Repurposed drugs in treating glioblastoma multiforme: clinical trials update
CN105943530A (zh) 铁死亡抑制剂在制备治疗铁过载疾病的药物中的应用
El-Desouky et al. The postulated mechanism of action of amygdalin (vitamin B17) on cancer cells